CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

News and Events

Latest News

Does the Evidence Support the Hype Around Antiviral Treatments for COVID-19?

May 27, 2020
Media Advisory Huge response to upcoming CADTH webinar on remdesivir and hydroxychloroquine shows demand among health care decision-makers for evidence on the effectiveness of these therapies. Ottawa, Ontario — More than 1,500 people have registered for a CADTH webinar that will provide an overview of the available science behind remdesivir an...

Patient Input and Clinical Experts: Zolgensma

May 26, 2020
CADTH has received the following notice(s) of pending drug submission(s). Brand name Zolgensma Generic name onasemnogene abeparvovec Manufacturer Novartis Pharmaceuticals Canada Inc. Indication(s) Spinal muscular atrophy (SMA), pediatrics Project Number SG0649-000 Call for pat...

Upcoming Events